ReviewFrontiers in immunology2024
The microbial damage and host response framework: lesson learned from pathogenic survival trajectories and immunoinflammatory responses of
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Using the Damage Response Framework as a Lens to Discuss Acinetobacter baumannii Host-Pathogen Interactions: A Narrative Review and a Call to Action.Infectious diseases and therapy · 2026Review
- Clinical Outcome After Surgery for Fracture-Related Infection Is Dependent on Both Microbiology and the Host Inflammatory Response.Pathogens (Basel, Switzerland) · 2026Article
- AIDS patients with Talaromycosis Marneffei exhibit inflammatory activation and depletion in their peripheral blood monocytes.PLoS neglected tropical diseases · 2026Article
- Helminth Immune Modulation and Invasive Fungal Infections in Sub-Saharan Africa.Journal of fungi (Basel, Switzerland) · 2026Article
- PANoptosis-mediated mechanisms underlying AST elevation in Talaromyces marneffei infection.PLoS neglected tropical diseases · 2025Article
- The dimorphic fungus Talaromyces marneffei: An opportunistic killer in Southeast Asia.PLoS pathogens · 2025Article
- Oxidative Stress Model of Lipopolysaccharide-Challenge in Piglets of Wuzhishan Miniature Pig.Veterinary sciences · 2025Article
- Article
- Species-specific circular RNA circDS-1 enhances adaptive evolution in Talaromyces marneffei through regulation of dimorphic transition.PLoS genetics · 2025Article
- Exploring the structural basis and functional immunodynamics of immunoglobulin M in host defense against fungal pathogens.Frontiers in immunology · 2025Review
- An overview of rapid non-culture-based techniques in various clinical specimens for the laboratory diagnosis ofFrontiers in cellular and infection microbiology · 2025Review
- Metagenomic Next-Generation Sequencing Unravels Talaromyces Marneffei-Induced Bone Destruction in an HIV-Negative Woman: A Case Report with Fatal Outcome.Infection and drug resistance · 2025Article
- Clinical and chest CT manifestations of Talaromycosis marneffei: a retrospective study comparing anti-IFN-γ autoantibodies-positive and HIV-positive cases.BMC infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adverse outcomes of fungal infection in mammalian hosts depend on the complex interactions between the host immune system and pathogen virulence-associated traits. The main clinical problems arise when the host response is either too weak to effectively eliminate the pathogen or overly aggressive, resulting in host tissue damage rather than protection. This article will highlight current knowledge regarding the virulence attributions and mechanisms involved in the dual-sided role of the host immune system in the immunopathogenesis of the thermally dimorphic fungus
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.